JP2014507147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507147A5 JP2014507147A5 JP2013553643A JP2013553643A JP2014507147A5 JP 2014507147 A5 JP2014507147 A5 JP 2014507147A5 JP 2013553643 A JP2013553643 A JP 2013553643A JP 2013553643 A JP2013553643 A JP 2013553643A JP 2014507147 A5 JP2014507147 A5 JP 2014507147A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- seq
- tfpi
- binds
- pathway inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091023037 Aptamer Proteins 0.000 claims description 51
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims description 32
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 18
- 238000006467 substitution reaction Methods 0.000 claims description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical group 0.000 claims description 9
- 208000032843 Hemorrhage Diseases 0.000 claims description 8
- 208000034158 bleeding Diseases 0.000 claims description 8
- 230000000740 bleeding effect Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 238000010348 incorporation Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 4
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 4
- 206010053567 Coagulopathies Diseases 0.000 claims description 4
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 4
- 208000009292 Hemophilia A Diseases 0.000 claims description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 230000037429 base substitution Effects 0.000 claims description 4
- 208000015294 blood coagulation disease Diseases 0.000 claims description 4
- 238000007385 chemical modification Methods 0.000 claims description 4
- 230000009852 coagulant defect Effects 0.000 claims description 4
- 208000009429 hemophilia B Diseases 0.000 claims description 4
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 206010067787 Coagulation factor deficiency Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 101000653189 Homo sapiens Tissue factor pathway inhibitor Proteins 0.000 claims description 2
- 208000034693 Laceration Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108700009202 Plasminogen Activator Inhibitor-1 Deficiency Proteins 0.000 claims description 2
- 208000027276 Von Willebrand disease Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 208000016804 acquired coagulation factor deficiency Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000011664 congenital factor XI deficiency Diseases 0.000 claims description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 2
- 201000007219 factor XI deficiency Diseases 0.000 claims description 2
- 208000002085 hemarthrosis Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 150000002634 lipophilic molecules Chemical class 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 208000007106 menorrhagia Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 229940012957 plasmin Drugs 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/026,165 US8598327B2 (en) | 2009-08-18 | 2011-02-11 | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| US13/026,165 | 2011-02-11 | ||
| PCT/US2012/024916 WO2012109675A1 (en) | 2011-02-11 | 2012-02-13 | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507147A JP2014507147A (ja) | 2014-03-27 |
| JP2014507147A5 true JP2014507147A5 (https=) | 2015-04-09 |
| JP6002691B2 JP6002691B2 (ja) | 2016-10-05 |
Family
ID=45771912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553643A Active JP6002691B2 (ja) | 2011-02-11 | 2012-02-13 | 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2673364A1 (https=) |
| JP (1) | JP6002691B2 (https=) |
| AU (1) | AU2012214148A1 (https=) |
| CA (1) | CA2827160A1 (https=) |
| WO (1) | WO2012109675A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010072691A1 (en) † | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| PT3345615T (pt) | 2010-03-01 | 2020-01-17 | Bayer Healthcare Llc | Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi) |
| AU2013235567A1 (en) * | 2012-03-22 | 2014-10-09 | Baxalta GmbH | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| CN111411164B (zh) * | 2020-05-26 | 2022-11-01 | 中国检验检疫科学研究院 | 利用数字pcr检测番茄溃疡病菌的方法及其使用的成套试剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| JP4663113B2 (ja) | 1997-09-05 | 2011-03-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用 |
| US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
| EP1919499A2 (en) * | 2005-07-29 | 2008-05-14 | Universiteit van Maastricht | Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor |
| KR101792032B1 (ko) * | 2008-12-19 | 2017-11-02 | 백스터 인터내셔널 인코포레이티드 | Ｔｆｐｉ 억제제 및 사용 방법 |
| FR2942232B1 (fr) * | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine de la coagulation et procedes pour sa mise en oeuvre |
| JP2013502218A (ja) * | 2009-08-18 | 2013-01-24 | バクスター・インターナショナル・インコーポレイテッド | 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用 |
-
2012
- 2012-02-13 WO PCT/US2012/024916 patent/WO2012109675A1/en not_active Ceased
- 2012-02-13 CA CA2827160A patent/CA2827160A1/en not_active Abandoned
- 2012-02-13 EP EP12706378.2A patent/EP2673364A1/en not_active Withdrawn
- 2012-02-13 AU AU2012214148A patent/AU2012214148A1/en not_active Abandoned
- 2012-02-13 JP JP2013553643A patent/JP6002691B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516680A5 (https=) | ||
| JP2012105650A5 (https=) | ||
| JP2011528913A5 (https=) | ||
| BR9708701A (pt) | Inibidores anti-sense de expressão do fator de crescimento endotelial vascular. | |
| JP2010539945A5 (ja) | 第Ｘａ因子阻害剤に対する解毒剤およびその使用の方法 | |
| JP2014507147A5 (https=) | ||
| RU2012110221A (ru) | Аптамеры к ингибитору пути тканевого фактора и их использование в качестве терапевтических агентов при нарушениях свертываемости | |
| JP2019504112A5 (https=) | ||
| JP2010534486A5 (https=) | ||
| JP2010519383A5 (https=) | ||
| JP2010166916A5 (https=) | ||
| JP2018502956A5 (https=) | ||
| JP2006513992A5 (https=) | ||
| ATE330967T1 (de) | An her2 bindende peptidverbindungen | |
| BR112013020273A2 (pt) | oligonucleotídeos antissenso | |
| JP2012255007A5 (https=) | ||
| MX2009000656A (es) | Acidos nucleicos que se fijan a sdf-i. | |
| JP2010530238A5 (https=) | ||
| JP2006506942A5 (https=) | ||
| JP2017523781A5 (https=) | ||
| JP2015532097A5 (https=) | ||
| RU2002130200A (ru) | Композиции для доставки лекарственного средства | |
| JP2009534451A5 (https=) | ||
| JP2011515357A5 (https=) | ||
| JP2013537404A5 (https=) |